Verastem, Inc. (VSTM) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Verastem, Inc. is a biopharmaceutical company focused on RAS/MAPK pathway-driven cancers. A pivotal event during the period was the May 8, 2025 FDA approval of AVMAPKI FAKZYNJA CO-PACK (avutometinib and defactinib) for the treatment of adult patients with KRAS mutant recurrent low-grade serous ovarian cancer (LGSOC). The company has initiated commercial sales in the U.S. and is advancing clinical trials for pancreatic cancer (RAMP 205) and non-small cell lung cancer (RAMP 203).
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Total Revenue | $2.1 million | $2.1 million | $10.0 million |
| Net Loss | $(25.9) million | $(78.0) million | $(42.1) million |
| Operating Expenses | $45.9 million | $90.1 million | $56.3 million |
| Cash & Equivalents (End of Period) | $164.3 million | $164.3 million | $89.1 million |
| Long-Term Debt | $74.3 million | $74.3 million | $40.7 million |
| Warrant Liability | $21.8 million | $21.8 million | $58.2 million |
Note: Revenue in Q2 2025 consists entirely of product sales. YTD 2024 revenue included a $10.0 million milestone payment from the sale of the COPIKTRA license.
Material Changes vs. Prior Period
- Revenue Shift: The company transitioned from milestone-based revenue (2024) to product revenue (2025). The $10.0 million milestone recognized in Q2 2024 did not recur in 2025.
- Expense Growth: Operating expenses increased significantly, driven by commercialization costs for the new product launch and R&D investments. Selling, General, and Administrative (SG&A) expenses rose 102% quarter-over-quarter to $20.7 million.
- Debt Restructuring: In January 2025, the company entered a new Note Purchase Agreement for $75.0 million and used proceeds to fully repay its previous Loan Agreement with Oxford Finance, resulting in a $1.8 million loss on debt extinguishment.
- Non-Cash Gains/Losses: The net loss was significantly impacted by non-cash items, including a $20.3 million gain from the change in fair value of warrant liability and a $3.0 million loss from the change in fair value of Notes.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern for 12 months following the issuance of these financial statements. This is due to anticipated continued operating losses and the need for additional capital to fund operations and clinical trials.
- Commercial Outlook: The company is focused on the commercial launch of AVMAPKI FAKZYNJA CO-PACK. It has submitted data to the National Comprehensive Cancer Network (NCCN) for inclusion in treatment guidelines.
- Clinical Pipeline:
- RAMP 301: Confirmatory Phase 3 trial for LGSOC; targeting full enrollment by end of 2025.
- RAMP 205: Pancreatic cancer trial; selected recommended Phase 2 dose with promising response rates.
- VS-7375: KRAS G12D inhibitor; first patient dosed in U.S. Phase 1/2a trial in June 2025.
- Risks: Key risks include the uncertainty of commercial success for the new product, potential delays in clinical trials, regulatory changes under the new U.S. administration, and the need to secure additional financing.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $164.3 million cash balance against the current burn rate (approx. $71 million cash used in operating activities for the first half of the year).
- Revenue Recognition: Confirm the trajectory of AVMAPKI FAKZYNJA CO-PACK sales and the impact of rebates and chargebacks on net revenue.
- Debt Covenants: Review the terms of the new Note Purchase Agreement, specifically the revenue participation payments (1% of net sales) and potential future tranches.
- Warrant Liability: Monitor the fair value of the warrant liability, which fluctuates with stock price and can significantly distort reported net loss.
- Going Concern Mitigation: Assess the probability and timing of future equity raises or strategic partnerships to resolve the going concern uncertainty.